M
Marc Ychou
Researcher at University of Montpellier
Publications - 251
Citations - 24302
Marc Ychou is an academic researcher from University of Montpellier. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 53, co-authored 234 publications receiving 20738 citations. Previous affiliations of Marc Ychou include ICM Partners & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more
TL;DR: FOLFIRINOX was associated with a survival advantage and had increased toxicity as compared with gemcitabine, and is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.
Journal ArticleDOI
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey,Eric Van Cutsem,Alberto Sobrero,Salvatore Siena,Alfredo Falcone,Marc Ychou,Yves Humblet,Olivier Bouché,Laurent Mineur,Carlo Barone,Antoine Adenis,Josep Tabernero,Takayuki Yoshino,Heinz-Josef Lenz,Richard M. Goldberg,Daniel J. Sargent,Frank Cihon,Lisa Cupit,Andrea Wagner,D. Laurent +19 more
TL;DR: Evidence is provided for a continuing role of targeted treatment after disease progression, with regorafenib offering a potential new line of therapy in this treatment-refractory population of patients with metastatic colorectal cancer.
Journal ArticleDOI
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Thierry Conroy,Pascal Hammel,Mohamed Hebbar,Meher Ben Abdelghani,Alice C. Wei,Jean-Luc Raoul,Laurence Chone,Eric Francois,Pascal Artru,James Joseph Biagi,Thierry Lecomte,Eric Assenat,Roger Faroux,Marc Ychou,Julien Volet,Alain Sauvanet,Gilles Breysacher,Frédéric Di Fiore,Christine Cripps,Petr Kavan,Patrick Texereau,Karine Bouhier-Leporrier,Faiza Khemissa-Akouz,Jean-Louis Legoux,Beata Juzyna,Sophie Gourgou,Christopher J. O'Callaghan,Claire Jouffroy-Zeller,Patrick Rat,David Malka,Florence Castan,Jean-Baptiste Bachet +31 more
TL;DR: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects.
Journal ArticleDOI
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou,Valérie Boige,Jean-Pierre Pignon,Thierry Conroy,Olivier Bouché,Gilles Lebreton,Muriel Ducourtieux,Laurent Bedenne,Jean-Michel Fabre,B. Saint-Aubert,Jean Genève,Philippe Lasser,Philippe Rougier +12 more
TL;DR: In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.
Journal ArticleDOI
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Astrid Lièvre,Jean-Baptiste Bachet,Valérie Boige,Anne Cayre,Delphine Le Corre,Emmanuel Buc,Marc Ychou,Olivier Bouché,Bruno Landi,Christophe Louvet,Thierry André,Frédéric Bibeau,Marie-Danièle Diebold,Philippe Rougier,Michel Ducreux,Gorana Tomasic,Jean-François Emile,Frédérique Penault-Llorca,Pierre Laurent-Puig +18 more
TL;DR: These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetUXimab.